Tesamorelin in Sweden: regulatory status

If you are in Sweden and researching tesamorelin, the regulatory picture is straightforward but worth spelling out in full: there is no authorised tesamorelin product in Sweden, in the EU, or anywhere in the EEA. The only marketing authorisation for tesamorelin that exists anywhere in the world is the United States approval for Egrifta, granted by the FDA in November 2010 for HIV-associated lipodystrophy^[2]. The European application was withdrawn by the applicant in June 2012 before the EMA reached a final decision^[1].

This article covers what happened at the EMA in 2012, how Swedish medicines law treats a product with no EU authorisation, what the named-patient route looks like in practice, and what changed in the past twelve months for Swedish readers asking about this peptide. This is not medical advice. Any decision about tesamorelin belongs with a prescribing clinician who knows your situation and your history.

What tesamorelin is and what the approved indication covers

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH), specifically the 44-amino-acid GHRH sequence with a trans-3-hexenoic acid group that extends its half-life. The FDA-approved indication is narrow: reduction of excess abdominal fat (visceral adipose tissue, or VAT) in adults with HIV who are on antiretroviral therapy and have developed lipodystrophy-pattern fat accumulation^[2]. It is not approved for general body-composition improvement, anti-ageing, sleep enhancement, or any of the off-label purposes for which it is most often discussed online.

The two pivotal Phase 3 trials, described in the 2012 review by Spooner and Olin, showed that 2 mg daily subcutaneous tesamorelin over 26 weeks produced a statistically and clinically meaningful reduction in VAT in HIV-positive adults with lipodystrophy, compared with placebo. A 2026 meta-analysis of randomised controlled trials confirmed reductions in VAT of approximately 27.7 cm2, trunk fat of 1.18 kg, and a gain in lean body mass of 1.42 kg, without significant changes in blood glucose^[4]. Those are the numbers the evidence supports in the approved population. They do not transfer automatically to healthy adults or to other indications.

The EMA application and why it was withdrawn in 2012

Theratechnologies, the Canadian company that developed tesamorelin, partnered with Ferrer Internacional for the European regulatory application. The EMA's Committee for Medicinal Products for Human Use (CHMP) began its review, but before the committee reached a formal opinion, Ferrer Internacional withdrew the application on 21 June 2012^[1]. The applicant cited the CHMP's preliminary position that the data did not allow the committee to conclude on a positive benefit-risk balance.

The CHMP's concerns centred on three areas. First, the clinical meaningfulness of the VAT reduction: showing a fat-depot change on imaging did not, in the committee's view, translate to a demonstrated health benefit for patients^[1]. Second, the representativeness of the trial population: the Phase 3 participants had larger abdominal fat deposits than European HIV patients typically present with, which made it difficult to assess how the benefit-risk balance would play out in the EU setting. Third, elevated IGF-1 levels in a meaningful proportion of treated patients raised long-term safety concerns, including potential cancer risk and worsening of diabetic eye disease.

No re-application has followed. As of July 2026, the EMA medicines register lists Egrifta under a withdrawn application, not an authorised product. That status has not changed in fourteen years.

How Swedish medicines law applies when there is no EU authorisation

Sweden implements EU medicines law through Lag (2015:315) om läkemedel and related regulations. The Läkemedelsverket (the Swedish Medical Products Agency, MPA) is the national competent authority. For a medicine to be lawfully placed on the market in Sweden, it must hold either a centralised EU authorisation via the EMA or a national authorisation granted by the MPA. Tesamorelin holds neither. That makes it an unlicensed medicine (licensläkemedel) under Swedish law^[1].

General sale and commercial supply of tesamorelin in Sweden is not lawful. A pharmacy cannot stock it. An online vendor in another country cannot lawfully supply it to a Swedish buyer. The product exists outside the normal medicines-regulation framework entirely.

Lawful access, if any, runs only through the named-patient (licensläkemedel) route. Under this route, a licensed Swedish prescriber may apply to the MPA for permission to import a specific unlicensed medicine for a specific named patient, taking personal responsibility for the prescribing decision. The application must document why no authorised alternative exists that meets the patient's needs. The route is designed for documented clinical situations, not for off-label or wellness use. See the tesamorelin regulation overview for the cross-country picture.

What changed in the past twelve months

For Sweden specifically, the regulatory position has not shifted. The EMA withdrawal from 2012 stands, no sponsor has re-submitted a European application, and the MPA has not taken any country-specific action on tesamorelin. What has changed is the broader conversation: tesamorelin has moved from a relatively obscure HIV-clinic peptide to a substance actively discussed in performance and longevity spaces online, which is the background against which Swedish readers are now encountering it.

On the research side, the 2026 meta-analysis by Badran and colleagues, published in Obesity Research and Clinical Practice, updated the evidence base for the HIV-lipodystrophy indication with confirmation of the VAT reduction, the lean-mass gain, and the hepatic fat reduction across pooled trial data^[4]. That is a consolidation of the existing approved indication, not an expansion. There is no published data on tesamorelin in healthy Swedish adults or in any indication other than HIV-associated lipodystrophy that would form the basis for a new European regulatory submission.

The grey-market dimension has also grown. Research-chemical vendors in the US and elsewhere market tesamorelin to European buyers, sometimes framing the US FDA approval as a signal that the compound is generally safe or legal. That framing is inaccurate. The FDA approval is narrow, jurisdiction-specific, and does not confer any legal status in Sweden. A Swedish buyer ordering tesamorelin online is acquiring an unlicensed medicine through an unlawful channel regardless of the vendor's country of registration.

Who to talk to in Sweden

If you have a clinical situation involving HIV-associated lipodystrophy and want to explore whether tesamorelin is accessible through the named-patient route, the conversation starts with a Swedish prescriber familiar with HIV medicine and the MPA licensing process. The MPA publishes guidance on the named-patient application process on its website. General enquiries about the regulatory status of a specific substance can also be directed to the MPA directly. The relevant page on this site is the Sweden regulation hub for the broader country-level framework.

If your interest is off-label, for body composition, anti-ageing, or related purposes: no Swedish prescriber can lawfully write a named-patient licence for a use that has no clinical evidence base and no regulatory precedent. The off-label framing does not open a legal access route in Sweden.

What we do not yet know

Whether Theratechnologies or any other sponsor will pursue an EU or EEA marketing authorisation for tesamorelin is not currently known. The company has focused on the US market and on Egrifta SV (a reconstituted-cartridge formulation approved by the FDA in 2019). No public indication of an EMA re-submission timeline has been given. If that changes, the MPA would be the starting point for Swedish prescribers and patients.

The long-term cancer-incidence data for tesamorelin outside the approved indication is also a gap. The CHMP raised IGF-1 elevation as a concern in 2012, and that concern applies with more force in non-HIV populations where the background risk profile differs from the approved indication. No long-term oncological follow-up data in healthy adults has been published.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Tesamorelin is an unlicensed medicine in Sweden. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Regulatory disclaimer: This page reflects our understanding of Swedish regulatory status as of 2026-07-21. Regulations change. Verify current status with the Läkemedelsverket or a qualified Swedish lawyer before making any decision.